search
Back to results

Treatment of Melasma With Glycolic Acid-Salicylic Acid Peel Versus Glycolic Acid Peel

Primary Purpose

Melasma

Status
Withdrawn
Phase
Early Phase 1
Locations
Study Type
Interventional
Intervention
Glycolic acid peel alone
Glycolic and salicylic acid peel
Sponsored by
Boston Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Melasma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Female and males aged 18 or older
  • Subjects with melasma on both sides of the face (forehead or cheek).
  • Subjects in general good health
  • Female of childbearing age will be on a reliable form of contraception during the course of treatment other than oral contraceptive pills or hormonal intrauterine device.
  • Subjects must be willing to sign consent, answer questionnaires, comply with all clinical visits, and use sunscreen and sun-protection.
  • Subjects must be willing to not apply other treatment options for melasma during the course of the study

Exclusion Criteria:

  • Subjects suffering from other pigmentation disorders.
  • Subjects with known allergy to any components of the peels
  • Subjects who have active uncontrolled disease to facial area (i.e acne).
  • Pregnant women, nursing mothers.
  • Subjects with history of abnormal scaring
  • Subjects who cannot communicate with investigators or who are unlikely to cooperate.
  • Subjects in a situation in which in the opinion of the investigators, may interfere with optimal participation in the study.
  • Subjects who have used chemical peels, microdermabrasion or facial laser treatments in the past 3 months.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Experimental

    Arm Label

    Glycolic acid peel alone

    Glycolic and salicylic acid peel

    Arm Description

    One of two sides of the face will be randomly treated with glycolic acid peel 35% alone. This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals

    The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment. This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals.

    Outcomes

    Primary Outcome Measures

    Change in pigmentation
    Change in pigmentation using a colorimeter

    Secondary Outcome Measures

    Change in pigmentation score
    Change in pigmentation using the Melasma Area and Severity Index (MASI)
    Improvement of melasma
    Improvement of melasma based on Patient and Physician Global assessment
    Adverse events assessment
    Patient questionnaire to assess for any adverse events encountered

    Full Information

    First Posted
    October 28, 2015
    Last Updated
    June 22, 2018
    Sponsor
    Boston Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02812719
    Brief Title
    Treatment of Melasma With Glycolic Acid-Salicylic Acid Peel Versus Glycolic Acid Peel
    Official Title
    Comparing the Efficacy and Safety of Combined Glycolic Acid and Salicylic Acid Peel Versus Glycolic Acid Peel Alone in the Treatment of Melasma: A Split Face Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2018
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Study did not receive funding and will not be implemented.
    Study Start Date
    July 2018 (Anticipated)
    Primary Completion Date
    December 2018 (Anticipated)
    Study Completion Date
    February 2019 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boston Medical Center

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    Yes
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The aim of this pilot study is to conduct a controlled comparison of the efficacy and safety of a combination peel (glycolic acid and salicylic acid) as compared to glycolic acid peel alone in the treatment of melasma. Our primary outcome is objective improvement in pigmentation as evaluated using a colorimeter. Our secondary outcomes are subjective improvement using the Melasma Area and Severity Index (MASI) and Patient and Physician Global assessment, as well as assessment of treatment tolerability and patient satisfaction.
    Detailed Description
    Melasma is an acquired form of hyperpigmentation that is seen most commonly on the face, characterized by symmetrically distributed brown patches of variable darkness. The cosmetically unattractive nature of this disorder has been shown to negatively affect a patient's quality of life. Unfortunately, the treatment of melasma is challenging and often disappointing. Treatment includes a combination approach with strict sun protection, cosmetic camouflage, topical lightening agents, laser therapy, and chemical peels. Today, the investigators define chemical peeling as the application of chemical exfoliating agents to the skin, which results in destruction of one or more parts of the epidermis and/or dermis with subsequent regrowth of these layers. Chemical peels are divided into superficial (light), medium, and deep; with superficial peels being the focus of this study. Superficial peels penetrate into the epidermis only, and are a safe, widely available and well-tolerated treatment modality. These peeling agents include glycolic acid, lactic acid, mandelic acid, salicylic acid and trichloroacetic acid, each with unique properties. For instance, alpha-hydroxy acids, such as glycolic acid, are known to be hydrophilic, whereas salicylic acid is lipophilic and anti-inflammatory. As each peeling agent has unique properties, it can be hypothesized that the combined use of these agents may result in better clinical outcomes than the use of an agent alone. Prior studies have demonstrated that the combined use of these peels are safe and effective in improving a variety of skin conditions including acne scars, hyperpigmentation, and infraorbital dark circles. Overall however, studies on the combined use of these chemical peels in the treatment of melasma are lacking. Therefore, the aim of this pilot study is to conduct a controlled comparison of the efficacy and safety of a combination peel (glycolic acid and salicylic acid) as compared to glycolic acid peel alone in the treatment of melasma.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Melasma

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Early Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    Investigator
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Glycolic acid peel alone
    Arm Type
    Active Comparator
    Arm Description
    One of two sides of the face will be randomly treated with glycolic acid peel 35% alone. This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals
    Arm Title
    Glycolic and salicylic acid peel
    Arm Type
    Experimental
    Arm Description
    The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment. This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals.
    Intervention Type
    Drug
    Intervention Name(s)
    Glycolic acid peel alone
    Other Intervention Name(s)
    Single acid skin peel
    Intervention Description
    One of two sides of the face will be randomly treated with glycolic acid peel 35% alone. This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals
    Intervention Type
    Drug
    Intervention Name(s)
    Glycolic and salicylic acid peel
    Other Intervention Name(s)
    Combination acid skin peel
    Intervention Description
    The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment. This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals.
    Primary Outcome Measure Information:
    Title
    Change in pigmentation
    Description
    Change in pigmentation using a colorimeter
    Time Frame
    Week 0, Week 7-8 (1-2 weeks following 4th peel), and Week 18 (12 weeks following 4th peel)
    Secondary Outcome Measure Information:
    Title
    Change in pigmentation score
    Description
    Change in pigmentation using the Melasma Area and Severity Index (MASI)
    Time Frame
    Week 0, Week 7-8 (1-2 weeks following 4th peel), and Week 18 (12 weeks following 4th peel)
    Title
    Improvement of melasma
    Description
    Improvement of melasma based on Patient and Physician Global assessment
    Time Frame
    Week 0 and Week 7-8 (1-2 weeks following 4th peel), and Week 18 (12 weeks following 4th peel)
    Title
    Adverse events assessment
    Description
    Patient questionnaire to assess for any adverse events encountered
    Time Frame
    Week 7-8 (1-2 weeks following 4th peel)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Female and males aged 18 or older Subjects with melasma on both sides of the face (forehead or cheek). Subjects in general good health Female of childbearing age will be on a reliable form of contraception during the course of treatment other than oral contraceptive pills or hormonal intrauterine device. Subjects must be willing to sign consent, answer questionnaires, comply with all clinical visits, and use sunscreen and sun-protection. Subjects must be willing to not apply other treatment options for melasma during the course of the study Exclusion Criteria: Subjects suffering from other pigmentation disorders. Subjects with known allergy to any components of the peels Subjects who have active uncontrolled disease to facial area (i.e acne). Pregnant women, nursing mothers. Subjects with history of abnormal scaring Subjects who cannot communicate with investigators or who are unlikely to cooperate. Subjects in a situation in which in the opinion of the investigators, may interfere with optimal participation in the study. Subjects who have used chemical peels, microdermabrasion or facial laser treatments in the past 3 months.

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    16781293
    Citation
    Dominguez AR, Balkrishnan R, Ellzey AR, Pandya AG. Melasma in Latina patients: cross-cultural adaptation and validation of a quality-of-life questionnaire in Spanish language. J Am Acad Dermatol. 2006 Jul;55(1):59-66. doi: 10.1016/j.jaad.2006.01.049. Epub 2006 May 2.
    Results Reference
    background
    PubMed Identifier
    19746672
    Citation
    Berson DS, Cohen JL, Rendon MI, Roberts WE, Starker I, Wang B. Clinical role and application of superficial chemical peels in today's practice. J Drugs Dermatol. 2009 Sep;8(9):803-11.
    Results Reference
    background
    PubMed Identifier
    20889235
    Citation
    Kodali S, Guevara IL, Carrigan CR, Daulat S, Blanco G, Boker A, Hynan LS, Pandya AG. A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women. J Am Acad Dermatol. 2010 Dec;63(6):1030-5. doi: 10.1016/j.jaad.2009.12.027.
    Results Reference
    background
    PubMed Identifier
    12269877
    Citation
    Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg. 2002 Sep;28(9):828-32; discussion 832. doi: 10.1046/j.1524-4725.2002.02034.x.
    Results Reference
    background
    PubMed Identifier
    17524124
    Citation
    Soliman MM, Ramadan SA, Bassiouny DA, Abdelmalek M. Combined trichloroacetic acid peel and topical ascorbic acid versus trichloroacetic acid peel alone in the treatment of melasma: a comparative study. J Cosmet Dermatol. 2007 Jun;6(2):89-94. doi: 10.1111/j.1473-2165.2007.00302.x.
    Results Reference
    background
    PubMed Identifier
    9935087
    Citation
    Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999 Jan;25(1):18-22. doi: 10.1046/j.1524-4725.1999.08145.x.
    Results Reference
    background
    PubMed Identifier
    14725662
    Citation
    Lee HS, Kim IH. Salicylic acid peels for the treatment of acne vulgaris in Asian patients. Dermatol Surg. 2003 Dec;29(12):1196-9; discussion 1199. doi: 10.1111/j.1524-4725.2003.29384.x.
    Results Reference
    background

    Learn more about this trial

    Treatment of Melasma With Glycolic Acid-Salicylic Acid Peel Versus Glycolic Acid Peel

    We'll reach out to this number within 24 hrs